Ascenta Finance Corp
Banner.jpg

PREVECEUTICAL

PREVECEUTICAL MEDICAL INC.
Raise of Up To $1,000,000

The Offering:

  • Up to 25,000,000 units (each a “Unit”) priced at $0.04 per Unit

  • Each Unit consists of one common share (each a “Share”) and one half of one share purchase warrant (each whole warrant, a “Warrant”)

  • Each Warrant is exercisable at a price of $0.06 for a period of 24 months from the closing of the Financing

  • Warrants can be accelerated if the closing price of the Company’s common shares on the Canadian Securities Exchange is $0.18 or greater for a minimum of ten consecutive trading days and a notice of acceleration is provided in accordance with the terms of the Warrants

About PreveCeutical Inc.:

PreveCeutical Medical Inc. (“PreveCeutical” or the “Company”) is a health sciences company that develops innovative options for preventive and curative therapies utilizing organic and nature identical products. PreveCeutical aims to be a leader in preventive health sciences and currently has five research and development programs, including: dual gene therapy for curative and prevention therapies for diabetes and obesity; the Sol-gel Program; Nature Identical™ peptides for treatment of various ailments; nonaddictive analgesic peptides as a replacement to the highly addictive analgesics such as morphine, fentanyl and oxycodone; and a therapeutic product for treating athletes who suffer from concussions (mild traumatic brain injury).

Click Here to view the PreveCeutical website
Click Here to view the PreveCeutical Investor Deck

Exchange: CSE
Symbol: PREV
Current Share Price: $0.03

Corporate Structure:

Plan of Arrangement with BioGene Therapeutics Inc.:

PrevaCeutical entered into a definitive arrangement agreement dated September 3, 2025 with its subsidiary, BioGene Therapeutics Inc. (“BioGene”), pursuant to which PreveCeutical intends to spin-out 12,000,000 common shares of BioGene (the “BioGene Spinout Shares”) to the shareholders of PreveCeutical (the “PreveCeutical Shareholders”) on a pro rata basis by way of a share capital reorganization effected through a statutory plan of arrangement (the “Arrangement”) pursuant to the Business Corporations Act (British Columbia) (the “BCBCA”). PreveCeutical received the BioGene Spinout Shares on November 15, 2024, in consideration for the sale of certain intellectual property assets to BioGene.

Pursuant to the Arrangement Agreement, PreveCeutical will, among other things, conduct a share capital reorganization whereby the existing common shares of PreveCeutical (the “PreveCeutical Shares”) will be renamed and redesignated as Class A common shares (each, a “PreveCeutical Class A Share”) and a new class of voting common shares (each, a “New PreveCeutical Share”) will be created. Each PreveCeutical Class A Share will be exchanged for one New PreveCeutical Share, and the number of BioGene Spinout Shares, which is equal to 12,000,000, divided by the number of issued and outstanding PreveCeutical Class A Shares on the effective date of the Arrangement. Once the Arrangement is complete, PreveCeutical Shareholders will own shares in two companies: BioGene, which will focus on the development of the Dual Gene Therapy program, and PreveCeutical, which will continue to focus on developing innovative options for preventive and curative therapies utilizing organic and nature identical products.

For more information on the Plan of Arrangement, please see:

PLEASE NOTE THAT MEMBERS OF
ASCENTA MAY PARTICIPATE IN THIS OFFERING.

The Company has agreed to pay Ascenta a finder’s fee of 8% cash and 8% brokers warrants.

The statements and statistics contained herein were obtained from sources believed to be reliable, but Ascenta cannot represent that they are accurate or complete.

THIS INVESTMENT IS RISKY AND YOU COULD LOSE YOUR ENTIRE INVESTMENT AMOUNT.  
Consult with your investment advisor, legal or tax professionals before investing.